Company: MIRM
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001759425-25-000054
Chunk: 344

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 344
---
ance of common stock in connection with equity award plans1,255,533— 16,096 — — 16,096 Conversion of convertible notes, net251— 8 — — 8 Stock-based compensation—— 18,194 — — 18,194 Net income—— — 2,905 — 2,905 Other comprehensive loss—— — — (315)(315)Balance as of September 30, 2025 51,314,176$5 $953,818 $(661,814)$37 $292,046 

 Common StockAdditionalPaid-InCapitalAccumulatedDeficit AccumulatedOtherComprehensiveIncome (Loss)TotalStockholders’Equity  SharesAmountBalance as of December 31, 2023 46,723,143$5 $803,260 $(556,239)$1,644 $248,670 Issuance of common stock in connection with equity award plans337,963— 1,205 — — 1,205 Stock-based compensation—— 11,664 — — 11,664 Net loss—— — (25,279)— (25,279)Other comprehensive loss—— — — (1,657)(1,657)Balance as of March 31, 202447,061,1065 816,129 (581,518)(13)234,603 Issuance of common stock in connection with equity award plans442,652— 5,858 — — 5,858 Issuance of common stock in connection with employee stock purchase plan68,089— 1,433 — — 1,433 Stock-based compensation—— 12,196 — — 12,196 Net loss—— — (24,638)— (24,638)Other comprehensive loss—— — — (464)(464)Balance as of June 30, 202447,571,8475 835,616 (606,156)(477)228,988 Issuance of common stock in connection with equity award plans396,274— 3,863 — — 3,863 Stock-based compensation—— 12,011 — — 12,011 Net loss—— — (14,235)— (14,235)